Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Trastuzumab in Plasma HER2-Amplified Advanced Breast Cancer
NCT05020964Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2021
- Primary completion
- Sep 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05020964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020964.